– USA, NY – Iveric Bio, Inc. (Nasdaq: ISEE) today announced the election of Christine Miller to its Board of Directors, effective immediately.
“We are excited to welcome Christine, a highly-qualified executive in the life-science industry, to our Board of Directors. Christine’s leadership, commercial and supply chain management experience and commitment to patients will serve us well as we prepare for a potential launch of Zimura (avacincaptad pegol) in geographic atrophy secondary to age-related macular degeneration. We believe the addition of Christine to our Board of Directors is part of our continued commitment to build a strong Board of Directors that can guide the growth of the Company and best represent our shareholders,” said CEO, Glenn Sblendorio.
About Christine Ann Miller
A global pharmaceutical veteran with more than 20 years of experience in life sciences, Ms. Miller is President and CEO of Melinta Therapeutics LLC, a company focused on the development and commercialization of innovative therapies for acute and life-threatening illnesses.
“I am thrilled to join the impressive Iveric Bio board and to have the opportunity to work with a highly-dedicated executive team at this pivotal time. “I look forward to contributing my insight and expertise to a Company that is committed to delivering treatments for debilitating retina diseases and having a positive impact on patients’ lives,” said Ms. Miller.
Before her role at Melinta Therapeutics, where she also serves on the Board of Directors, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was responsible for transitioning the portfolio toward rapid-growth and higher-margin segments such as complex generics and value-added medicines while continuing to build the branded generics business. Her achievements at Sandoz included directing more than 50 product launches that generated over $300 million of new annual revenue, closing numerous business development acquisitions, and building a robust five-year development and acquisition product pipeline.
In addition to her work at Sandoz, Ms. Miller spent over a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals, where she led the preparation of numerous product launches and held leadership roles in both R&D operations and supply chain management. She began her career as a chemical engineer and procurement analyst at Merck.
Ms. Miller earned an MBA and a Master’s in Technology Management at Stevens Institute of Technology and a BS in Chemical Engineering from Rensselaer Polytechnic Institute.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe,d effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration.
For more information: ttps://ivericbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.